Mark W Majewski
Overview
Explore the profile of Mark W Majewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majewski M, Gandhi D, Holyst T, Wang Z, Hernandez I, Rosas Jr R, et al.
RSC Med Chem
. 2021 Jan;
11(8):940-949.
PMID: 33479689
Unpublished data from our labs led us to hypothesize that activated protein C (aPC) may initiate an anti-inflammatory signal in endothelial cells by modulating both the integrin αVβ3 and protease-activated...
2.
Majewski M, Gandhi D, Rosas Jr R, Kodali R, Arnold L, Dockendorff C
ACS Med Chem Lett
. 2019 Jan;
10(1):121-126.
PMID: 30655958
A novel class of bivalent ligands targeting putative protease-activated receptor (PAR) heteromers has been prepared based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of the PAR1...
3.
Gandhi D, Majewski M, Rosas Jr R, Kentala K, Foster T, Greve E, et al.
Bioorg Med Chem
. 2018 Apr;
26(9):2514-2529.
PMID: 29685684
Several classes of ligands for Protease-Activated Receptors (PARs) have shown impressive anti-inflammatory and cytoprotective activities, including PAR2 antagonists and the PAR1-targeting parmodulins. In order to support medicinal chemistry studies with...
4.
Majewski M, Miller P, Miller M
J Antibiot (Tokyo)
. 2016 Dec;
70(3):292-296.
PMID: 27999444
Classically, β-lactams need an ionizable group to potentiate antibacterial activity. Sets of cephalosporins and penicillins featuring different substituted hydroxamates in place of the traditional carboxylate group have been synthesized and...
5.
Majewski M, Miller P, Oliver A, Miller M
J Org Chem
. 2016 Dec;
82(1):737-744.
PMID: 27935702
The synthesis of a small set of β-lactams containing isocyanate precursors is described. The release of the isocyanate precursor in model hydrolysis experiments was substantiated by trapping experiments, thus confirming...
6.
Majewski M, Tiwari R, Miller P, Cho S, Franzblau S, Miller M
Bioorg Med Chem Lett
. 2016 Mar;
26(8):2068-71.
PMID: 26951749
Tuberculosis (TB) remains one of the most threatening diseases in the world and the need for development of new therapies is dire. Herein we describe the rationale for the design...
7.
Majewski M, Watson K, Cho S, Miller P, Franzblau S, Miller M
Medchemcomm
. 2016 Feb;
7(1):141-147.
PMID: 26918106
Both the resurgence of tuberculosis (TB) and antibiotic resistance continue to threaten modern healthcare and new means of combating pathogenic bacterial infections are needed. The syntheses of monobactams possessing hydroxamate...
8.
Majewski M, Cho S, Miller P, Franzblau S, Miller M
Bioorg Med Chem Lett
. 2015 Jun;
25(21):4933-4936.
PMID: 26037320
Tuberculosis (TB) continues to remain one of the most threatening diseases in the world. With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains, the need to...